Clinical Trial

Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)

Name: Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV) — clinical trial record (NCT07688980)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to assess the PK, PD, and safety of anifrolumab as SC administration or IV infusion in adult participants with systemic lupus erythematosus (SLE).

Trial Details

NCT Number	NCT07688980
Lead Sponsor	AstraZeneca Collaborators: Parexel
Conditions	Systemic Lupus Erythematosus
Enrollment	92 participants
Start Date	2026-10-30
Primary Completion	2029-04-13 (estimated)
Study Completion	2030-06-14 (estimated)
Updated on ClinicalTrials.gov	2026-07-07